Is this your company? Get featured or correct your listing →
Recent changes
- Jul 2, 2026Jul 2, 2026Invested in Beeline Medicines (extension, $126M) Crunchbase News
Latest Pulse
- Sep 9, 2026MapLight Therapeutics Files For $150M Follow-On RaiseMapLight Therapeutics, which IPO'd on Nasdaq in October 2025, filed a new S-1 for a $150 million follow-on financing ahead of Phase 2 schizophrenia data expected later this year.→
- Aug 5, 2026Braveheart Bio Prices $300M IPO for Heart DrugBraveheart Bio priced 18.75M shares at $16 to raise $300M on Nasdaq, funding its lead drug BHB-1893 for hypertrophic cardiomyopathy in the same week two other biotechs also priced.→
- Jul 29, 2026Breakthru Medicine Launches With $60M Molecular Glue BetBreakthru Medicine emerged from stealth with a $60 million Series A to build a molecular glue platform and a pipeline of small molecules and antibody-drug conjugate payloads.→
- Jul 1, 2026Bain, CPP and Bristol Myers Add $126M to Beeline's Lupus PipelineBeeline Medicines closed a $126.3 million Series A extension from Bain Capital, CPP Investments and Bristol Myers Squibb, upsizing its total Series A to $426.3 million to fund pivotal development of afimetoran in lupus ahead of a Phase 2 readout expected in.→
Coverage Timeline
newest firstAll Coverage
Related Companies
Bristol Myers Squibb FAQ
Is Bristol Myers Squibb publicly traded?
Yes. Bristol Myers Squibb trades.